Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Dual role of Response gene to complement-32 in multiple sclerosis.
Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave Dreams Study (Brain Venous Drainage Exploited Against Multiple Sclerosis): study protocol for a randomized controlled trial.
The occurrence of dystonia in upper-limb multiple sclerosis tremor.
Inhibition of autoimmune encephalomyelitis by a tetracycline.
Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
MARINOL®
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells.
Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats.
FDA approves first oral drug to reduce MS relapses
Evaluation of serum oxidant/antioxidant balance in multiple sclerosis.
Epstein-Barr virus latent membrane protein 2A exacerbates experimental autoimmune encephalomyelitis and enhances antigen presentation function.
Quantitative structure-activity relationship studies on sulfonamide-based MMP inhibitors.
Multiple sclerosis and pain.
Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model.
An evidence-based review of natalizumab therapy in the management of Crohn's disease.
Longitudinal extensive transverse myelitis and optic neuritis: the elements for the diagnosis of neuromyelitis optica.
A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue.
Overview of the biology of type I interferons.
The spectrum of MOG autoantibody-associated demyelinating diseases.
[Chronic cerebrospinal venous insufficiency--pathophysiology and treament].
Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis.
France Banned AB Science Drug Studies Because of Side Effects
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
Plasma chemerin levels in patients with multiple sclerosis.

Pages